Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculations

作者: Edithe Selwa , Eddy Elisée , Agustin Zavala , Bogdan I. Iorga

DOI: 10.1007/S10822-017-0054-1

关键词:

摘要: Our participation to the D3R Grand Challenge 2 involved a protocol in two steps, with an initial analysis of available structural data from PDB allowing selection most appropriate combination docking software and scoring function. Subsequent calculations showed that pose prediction can be carried out certain precision, but this is dependent on specific nature ligands. The correct ranking poses still problem cannot successful absence good predictions. free energy different subsets provided contrasted results, which might have origin non-optimal force field parameters associated sulfonamide chemical moiety.

参考文章(49)
Wendong Huang, Yan-Dong Wang, Wei-Dong Chen, FXR, a target for different diseases. Histology and Histopathology. ,vol. 23, pp. 621- 627 ,(2008) , 10.14670/HH-23.621
Vytautas Gapsys, Servaas Michielssens, Jan Henning Peters, Bert L. de Groot, Hadas Leonov, Calculation of binding free energies. Methods of Molecular Biology. ,vol. 1215, pp. 173- 209 ,(2015) , 10.1007/978-1-4939-1465-4_9
Arun J. Sanyal, Use of Farnesoid X Receptor Agonists to Treat Nonalcoholic Fatty Liver Disease Digestive Diseases. ,vol. 33, pp. 426- 432 ,(2015) , 10.1159/000371698
Valentina Sepe, Eleonora Distrutti, Stefano Fiorucci, Angela Zampella, Farnesoid X receptor modulators (2011 - 2014): a patent review. Expert Opinion on Therapeutic Patents. ,vol. 25, pp. 885- 896 ,(2015) , 10.1517/13543776.2015.1045413
Claire Colas, Bogdan I. Iorga, Virtual screening of the SAMPL4 blinded HIV integrase inhibitors dataset Journal of Computer-aided Molecular Design. ,vol. 28, pp. 455- 462 ,(2014) , 10.1007/S10822-014-9707-5
Andrea Mencarelli, Stefano Fiorucci, FXR an emerging therapeutic target for the treatment of atherosclerosis Journal of Cellular and Molecular Medicine. ,vol. 14, pp. 79- 92 ,(2010) , 10.1111/J.1582-4934.2009.00997.X
Shi-Ying Cai, James L Boyer, FXR: a target for cholestatic syndromes? Expert Opinion on Therapeutic Targets. ,vol. 10, pp. 409- 421 ,(2006) , 10.1517/14728222.10.3.409
João Soeiro Teodoro, Anabela Pinto Rolo, Carlos Marques Palmeira, Hepatic FXR: key regulator of whole-body energy metabolism Trends in Endocrinology & Metabolism. ,vol. 22, pp. 458- 466 ,(2011) , 10.1016/J.TEM.2011.07.002
Bertrand Cariou, Bart Staels, FXR: a promising target for the metabolic syndrome? Trends in Pharmacological Sciences. ,vol. 28, pp. 236- 243 ,(2007) , 10.1016/J.TIPS.2007.03.002
Song Feng, Minmin Yang, Zhenshan Zhang, Zhanguo Wang, Di Hong, Hans Richter, Gregory Martin Benson, Konrad Bleicher, Uwe Grether, Rainer E. Martin, Jean-Marc Plancher, Bernd Kuhn, Markus Georg Rudolph, Li Chen, Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist Bioorganic & Medicinal Chemistry Letters. ,vol. 19, pp. 2595- 2598 ,(2009) , 10.1016/J.BMCL.2009.03.008